Saphris (Asenapine) Withdrawal Symptoms: List Of Possibilities
Saphris (Asenapine) is a drug that was approved by the FDA in 2007 for the treatment of schizophrenia and the manic phases of bipolar disorder. It functions by acting primarily on 5-HT2A serotonergic...
View ArticleFanapt (Iloperidone) Withdrawal Symptoms: List Of Possibilities
Fanapt (Iloperidone) is an atypical antipsychotic that was approved by the FDA on May 6, 2009 for the treatment of schizophrenia. The drug is thought to have been synthesized in the 1990s, during...
View ArticleFanapt (Iloperidone) & Weight Gain: What Should You Expect?
Fanapt (Iloperidone) is an antipsychotic that was approved in 2009 for the treatment of schizophrenia. It functions similar to most current-market atypical antipsychotics in that it acts as an...
View ArticleInvega (Paliperidone) Withdrawal Symptoms: List of Possibilities
Invega (Paliperidone) is an atypical antipsychotic approved in 2006 for the treatment of schizophrenia. Several years later in 2009, a longer-acting format of the medication called “Invega Sustenna”...
View ArticleInvega (Paliperidone) & Weight Gain: What Should You Expect?
Invega (Paliperidone) is considered a newer spin-off of the antipsychotic Risperdal in that it contains the same active metabolite, but is thought to have fewer side effects and drug interactions. It...
View Article20+ New Schizophrenia Medications In Development (2015)
It is estimated that over 2.5 million adults in the United States have been diagnosed with schizophrenia; this equates to approximately 1.1% of the population. There are many different types of...
View Article3 New Bipolar Medications (2015): Drugs In Clinical Trials
Bipolar disorder is a condition characterized by cyclical mood swings, transitioning from depression to mania (or hypomania). For a period of time, an individual with bipolar disorder will experience...
View ArticleVraylar (Cariprazine) Approved For Schizophrenia & Bipolar Disorder
Vraylar (Cariprazine) was approved by the FDA on September 17, 2015 for the treatment of schizophrenia and mania associated with bipolar disorder. In clinical trials, the drug was referenced as...
View ArticleHow Long Does Abilify Stay In Your System After Stopping?
Abilify (Aripiprazole) is a medication that was developed by Otsuka Pharmaceuticals and approved by the FDA in 2002 for the treatment of schizophrenia. Approximately 2 years thereafter (in 2004) it...
View ArticleHow Long Does Seroquel Stay In Your System After Stopping?
Seroquel (Quetiapine) is a medication that was developed by AstraZeneca from 1992 through 1996. It received FDA approval in 1997 for the treatment of schizophrenia, and has since received approval to...
View ArticleSeroquel (Quetiapine) For Anxiety Disorders: An “Atypical” Treatment
Seroquel (Quetiapine) is an atypical antipsychotic engineered in the early 1990s by the pharmaceutical company AstraZeneca. It was first approved by the FDA in 1997 for the treatment of schizophrenia,...
View ArticleRexulti (Brexpiprazole) Withdrawal Symptoms: What You Should Know
Mental Health Daily Mental Health Daily - Rexulti (Brexpiprazole) is an atypical antipsychotic that is most commonly utilized as a pharmacologic intervention for the management of schizophrenia, and in...
View ArticleVraylar (Cariprazine) & Weight Gain vs. Loss: What You Should Know
MentalHealthDaily MentalHealthDaily - Vraylar (Cariprazine), also sold under the name Reagila [in European countries], is an atypical antipsychotic developed by the pharmaceutical company Allergan. In...
View ArticleVraylar (Cariprazine) Side Effects & Adverse Reactions
MentalHealthDaily MentalHealthDaily - Vraylar (Cariprazine), is an atypical antipsychotic medication approved in 2015 by the FDA for the treatment of schizophrenia and bipolar disorder. Occasionally,...
View ArticleVraylar (Cariprazine) Withdrawal Symptoms: What To Expect After Discontinuation
MentalHealthDaily MentalHealthDaily - Vraylar (Cariprazine) is an atypical antipsychotic that is most frequently prescribed as a pharmacological intervention for schizophrenia and bipolar disorder....
View ArticleMetformin Prevents Antipsychotic-Induced Weight Gain: A Saudi Study Finds
MentalHealthDaily MentalHealthDaily - Research suggests that metformin may reduce weight gain associated with antipsychotic medications. Key facts: Antipsychotics are linked to weight gain, especially...
View ArticleQuetiapine Dosing for Depression Optimized with XGBoost Algorithm (2024 Study)
MentalHealthDaily MentalHealthDaily - Depression is a globally pervasive mental illness that often requires complex treatment strategies. One such strategy involves the use of Quetiapine, an...
View ArticleComparison of Brexipiprazole vs. Aripiprazole for Treatment-Resistant...
MentalHealthDaily MentalHealthDaily - Antidepressant-resistant major depressive disorder (AR-MDD) poses significant challenges in psychiatric treatment. Antipsychotics like aripiprazole (ARI) and...
View ArticleHow People Feel About Antipsychotics & Mood Stabilizers: Twitter/X Sentiment...
MentalHealthDaily MentalHealthDaily - Social media has emerged as a pivotal source of real-world evidence, especially in understanding patient experiences and perceptions regarding the treatment of...
View ArticleQuetiapine-Induced Psychosis: A Rare Adverse Effect (2024 Case Report)
MentalHealthDaily MentalHealthDaily - Quetiapine, a second-generation antipsychotic medication, is renowned for its efficacy in managing a spectrum of psychiatric conditions, including schizophrenia,...
View Article